Senate Bill No. 253, introduced by Senator McMath, aims to regulate the use of peptides in healthcare by enacting R.S. 37:23.5. The bill stipulates that no professional or occupational licensing board can prohibit healthcare providers with prescriptive authority from prescribing peptides that are shipped from FDA-registered 503B facilities or 503A compounding pharmacies, provided these pharmacies source their active pharmaceutical ingredients from FDA-registered manufacturers.

Additionally, the bill mandates that prescribing providers must ensure that any peptides they prescribe are not included on the FDA's prohibited compounding list. This legislation is set to take effect on August 1, 2026, and seeks to clarify the legal framework surrounding the prescription of peptides, thereby enhancing patient access to these treatments while ensuring compliance with federal regulations.